# Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

> **NCT07453095** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 41 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Glofitamab

## Key facts

- **NCT ID:** NCT07453095
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2028-07-15
- **Final completion:** 2030-06-15
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07453095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07453095, "Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07453095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*